NEW YORK ( TheStreet) -- Savient Pharmaceuticals (Nasdaq: SVNT) hit a new 52-week low Tuesday as it is currently trading at $3.51, below its previous 52-week low of $3.53 with 1.7 million shares traded as of 2:15 p.m. ET. Average volume has been 1.8 million shares over the past 30 days. Savient has a market cap of $292.7 million and is part of the health care sector and drugs industry. Shares are down 66.6% year to date as of the close of trading on Monday. Savient Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing KRYSTEXXA, a biologic PEGylated uricase in the United States. The KRYSTEXXA is being developed as a treatment for chronic gout in patients refractory to conventional therapy.
Practice your SVNT trading strategies and win cash in our stock game.
TheStreet Ratings rates Savient as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally weak debt management and generally disappointing historical performance in the stock itself. You can view the full Savient Ratings Report. See all 52-week low stocks or get investment ideas from our investment research center.